Form 4 Filing for Coherus Oncology, Inc.

Mats Wahlstrom, a director at Coherus Oncology, Inc., reported a transaction on June 5, 2026. He acquired 30,000 shares of Common Stock, valued at $0 per share, under a restricted stock unit (RSU) agreement. These RSUs will vest on June 3, 2027, subject to his continued service. Additionally, Wahlstrom was granted a stock option to purchase 60,000 shares of Common Stock at an exercise price of $1.45 per share. This option has an expiration date of June 5, 2036, and the underlying shares will vest on June 3, 2027, contingent upon his continued employment. Both the RSUs and the stock option are classified as direct ownership.